NCT03408080View on ClinicalTrials.gov

Open Pilot Trial of BHV-4157

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

December 15, 2024

Study Completion Date

December 15, 2024

Conditions
Spinocerebellar AtaxiasSpinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 2Spinocerebellar Ataxia 3Spinocerebellar Ataxia Type 6MSA-C
Interventions
DRUG

BHV-4157

BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.

Trial Locations (1)

90095

University of California, Los Angeles, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER